Last reviewed · How we verify
Guselkumab Dose 1
Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.
At a glance
| Generic name | Guselkumab Dose 1 |
|---|---|
| Also known as | CNTO 1959, CNTO1959 |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | IL-23 inhibitor (monoclonal antibody) |
| Target | IL-23 (p19 subunit) |
| Modality | Small molecule |
| Therapeutic area | Immunology/Dermatology |
| Phase | Phase 3 |
Mechanism of action
Guselkumab binds to the p19 subunit of IL-23, a key cytokine involved in the differentiation and activation of pathogenic T helper 17 (Th17) cells. By inhibiting IL-23 signaling, the drug suppresses the inflammatory cascade underlying psoriasis and other immune-mediated conditions. This targeted approach reduces systemic inflammation while preserving other immune functions.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
- Injection site reactions
Key clinical trials
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2, PHASE3)
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PHASE3)
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- A Study of Guselkumab in Participants With Active Psoriatic Arthritis (PHASE3)
- A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |